Who are Abiraterone: Treatment A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NIRAPARIB, Abiraterone Acetate, Enzalutamide, Abiraterone, SoluMatrix™ Abiraterone Acetate, Fuzuloparib , Abiraterone acetate and Prednisone, Abiraterone Acetate or Enzalutamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abiraterone-treatment-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Abiraterone: Treatment A — Competitive Intelligence Brief

Abiraterone: Treatment A (Abiraterone: Treatment A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CYP17 inhibitor. Area: Oncology.

phase 1 CYP17 inhibitor CYP17 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Abiraterone: Treatment A (Abiraterone: Treatment A) — Janssen Research & Development, LLC. Inhibits CYP17, a key enzyme in the biosynthesis of androgens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abiraterone: Treatment A TARGET	Abiraterone: Treatment A	Janssen Research & Development, LLC	phase 1	CYP17 inhibitor	CYP17
NIRAPARIB	NIRAPARIB		marketed		PARP-1, PARP-2, CYP17	2017-01-01
Abiraterone Acetate	abiraterone	Pfizer	marketed	Androgen biosynthesis inhibitor	CYP17	2011-01-01
Enzalutamide, Abiraterone	Enzalutamide, Abiraterone	Veru Inc.	phase 3	Androgen receptor antagonist + CYP17A1 inhibitor combination	Androgen receptor (AR) and CYP17A1
SoluMatrix™ Abiraterone Acetate	SoluMatrix™ Abiraterone Acetate	GU Research Network, LLC	phase 3	CYP17 inhibitor	CYP17
Fuzuloparib , Abiraterone acetate and Prednisone	Fuzuloparib , Abiraterone acetate and Prednisone	Jiangsu HengRui Medicine Co., Ltd.	phase 3	PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone)	PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone)
Abiraterone Acetate or Enzalutamide	Abiraterone Acetate or Enzalutamide	National Cancer Institute, Naples	phase 3	Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide)	CYP17A1 (abiraterone) / Androgen receptor (enzalutamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CYP17 inhibitor class)

Cougar Biotechnology, Inc. · 2 drugs in this class
Janssen Research & Development, LLC · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
GU Research Network, LLC · 1 drug in this class
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abiraterone: Treatment A — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone-treatment-a. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab